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Abstract
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical 
industry’s investments in research and development (R&D). Information about the drugs being 
developed can provide important context for existing case studies detailing the expanding – and 
often problematic – role of pharmaceuticals in society. To access the pharmaceutical industry’s 
pipeline, we constructed a database of drugs for which pharmaceutical companies reported 
initiating clinical trials over a five-year period (July 2006-June 2011), capturing 2,477 different 
drugs in 4,182 clinical trials. Comparing drugs in the pipeline that target diseases in high-income 
and low-income countries, we found that the number of drugs for diseases prevalent in high-
income countries was 3.46 times higher than drugs for diseases prevalent in low-income countries. 
We also found that the plurality of drugs in the pipeline were being developed to treat cancers 
(26.2%). Interpreting our findings through the lens of pharmaceuticalization, we illustrate how 
investigating the entire drug development pipeline provides important information about patterns 
of pharmaceuticalization that are invisible when only marketed drugs are considered.
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Introduction
Within discourses about research and development (R&D), the pharmaceutical industry 
often represents the process as a pipeline, and a leaky one at that. In these depictions, 
clinical development - the part of R&D in which investigational drugs are tested on humans 
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- is divided into three phases with some drugs falling out of the pipe at each step as they 
move toward market approval. Phase I studies primarily rely on healthy volunteers to 
establish safety profiles for investigational drugs and to help establish appropriate doses that 
can be given to patients in subsequent clinical trials. A “failed” drug at this stage would be 
one that produces high rates of serious adverse events (i.e., side effects) in participants. 
Phase II trials enroll a small number of patients with the target illness in a proof-of-concept 
trial that aims to collect additional data on the safety of the investigational drug as well as 
preliminary evidence of its efficacy. Drugs that do not exhibit sufficient promise in treating 
the targeted illness or are not well tolerated by patients are likely to drop out of the pipeline 
at this stage. Phase III studies are large-scale clinical trials designed to show the 
investigational drug’s efficacy by comparing the outcomes of several hundred or more 
patients randomly assigned to receive the drug with a placebo and/or a competitor product. 
According to industry analysts, the probability that an investigational drug will transition 
from Phase I to Phase II is 71% and from Phase II to Phase III is 45% (DiMasi et al., 2010). 
Pharmaceutical companies submit applications to the U.S. Food and Drug Administration 
(FDA) to market approximately 64% of all drugs that enter Phase III trials (DiMasi et al., 
2010) (Figure 1). Although the FDA subsequently approves 93% of all such applications, 
these represent only 19% of all drugs that began clinical testing (DiMasi et al., 2010). In 
other words, more than 80% of all investigational drugs that enter the proverbial pipeline are 
likely to “leak out” and never make it to market.
The pharmaceutical industry claims that drug development is a high-risk activity, with 
lengthy and expensive clinical trials on which the success or failure of their products hinge. 
As part of this framing, the industry lobbying group PhRMA – as well as industry-
supported, academic economists – have circulated stunning estimates of costs associated 
with bringing new drugs to market (DiMasi et al., 2003; PhRMA, 2004, n.d.). DiMasi and 
colleagues (2003) estimated cost based on a sample of 68 self-originated new molecular 
entities (i.e., the most expensive drugs to develop) and calculated the average investment in 
a drug brought to market is $802 million. At the same time, consumer advocacy groups and 
industry critics – within and outside academia – challenge not only this projected average 
cost of drug development but also the therapeutic value of many new pharmaceuticals 
(Angell, 2004; Goozner, 2005; Light & Warburton, 2011). On this latter point, for example, 
Light, Lexchin, and Darrow (2013) have shown that only 8% of drugs approved by the FDA 
from 2002 to 2011 offer substantial therapeutic benefit for patients over existing products on 
the market and 15% were deemed to be more harmful than beneficial.
In spite of diverse groups’ interest in the process and politics of drug development, the 
pharmaceutical pipeline itself remains relatively black-boxed. In part, the pipeline metaphor 
works as a marketing tool for the industry, creating the impression that there is an endless 
supply of new and innovative products in development. In spite of the powerful imagery, 
there is much evidence to suggest that the number of investigational drugs is on the decline 
and those that make it to market offer few therapeutic breakthroughs for patients (Angell, 
2004; Light & Lexchin, 2012; Light & Warburton, 2011). In addition, the pharmaceutical 
industry places understandably more emphasis on promoting information about marketed 
products than those unable to meet FDA safety and efficacy benchmarks. Within social 
science and biomedical communities, scholarship has also centered on marketed 
Fisher et al. Page 2













pharmaceuticals, analyzing physicians’ relationships with industry, direct-to-consumer 
advertising, and industry constructions of illness (e.g., Conrad & Leiter, 2008; Dumit, 2012; 
Greene, 2007; Kassirer, 2005). This literature often mobilizes the concept of 
“pharmaceuticalization” to signal the increasing power of the pharmaceutical industry to 
shape physicians’ and patients’ engagement with health and illness (Abraham, 2010; Bell & 
Figert, 2012; Busfield, 2010; Williams, Gabe, and Davis, 2008; Williams et al., 2011). Even 
when this scholarship includes examinations of clinical trials, it often does so retrospectively 
either for marketed pharmaceuticals or those removed from the market due to safety 
concerns.
Given the dearth of information about the pharmaceutical pipeline, we constructed a 
database of drugs for which pharmaceutical companies reported initiating clinical trials over 
a five-year period (July 2006-June 2011), capturing 2,477 drugs being evaluated in 4,182 
clinical trials. Querying these data, we asked the following questions about drugs in the 
development pipeline: (1) Including Phase I, II, and III clinical trials, what therapeutic areas 
are targeted?; (2) To what extent does the distribution of disease categories reflect global 
disease burden?; and (3) What can be inferred about the pharmaceutical industry’s priorities 
for products they intend to market? Interpreting our findings through the lens of 
pharmaceuticalization, we argue that much of drug development focuses on illnesses 
prevalent in Western contexts, where drugs have more potential to generate significant 
revenue for pharmaceutical companies. We also illustrate how investigating the entire drug 
development pipeline provides important information about patterns of 
pharmaceuticalization that are invisible when only marketed drugs are considered.
Pharmaceuticalization and Drug Development
Sociological interest in the role of pharmaceuticals in medicine has emerged from a longer-
standing research tradition investigating the medicalization of society (Clarke et al., 2003; 
Conrad, 2007). This broader area of scholarship has shown how the profession of medicine 
has encroached on and claimed expertise over routine aspects of life from birth to death 
(e.g., Howarth, 2007; Starr, 1982; Sullivan & Weitz, 1988). Similarly, scholars have shown 
how pharmaceuticals have extended medicalization such that aging, sex, and sleep have all 
become problems requiring chemical intervention (Fishman et al., 2010; Fox & Ward, 2008; 
Healy, 2012; Marshall, 2002; Williams, Seale, et al., 2008). Williams, Martin, and Gabe 
(2011) define pharmaceuticalization as “the translation or transformation of human 
conditions, capabilities and capacities into opportunities for pharmaceutical intervention” 
(711). They further note that scholars must include in their analyses of 
pharmaceuticalization “both upstream (macro) level processes concerning the development, 
testing and regulation of pharmaceuticals and downstream (micro) processes pertaining to 
the meaning and use of pharmaceuticals in medical practice and everyday life” (711-2). 
More concretely, increased pharmaceutical use can enable further medicalization, such as 
the expanded use of drugs developed for depression being used to treat shyness in the form 
of “social anxiety disorder” and monthly PMS as “premenstrual dysphoric disorder” 
(Greenslit, 2005; Lane, 2008). In some instances, however, pharmaceuticalization occurs 
outside of the purview of the medical profession. Examples include increased consumer use 
of over-the-counter medications and recreational use of prescription drugs for erectile 
Fisher et al. Page 3













dysfunction and attention deficit hyperactivity disorder (ADHD) drugs for performance 
enhancement (Abraham, 2010; Loe, 2008; Race, 2009).
Most of the literature frames pharmaceuticalization as a negative trend. By simply watching 
U.S. television or reading newspapers, it is clear why many scholars are critical. 
Pharmaceutical companies develop and promote some products that seem to have frivolous 
uses and unnerving side effects, such as drugs for thickening eyelashes or eastbound travel-
induced jet lag (Pollack, 2010; Saint Louis, 2010). Even when the illnesses targeted by 
pharmaceuticals are relevant to significant morbidity and mortality, aggressive marketing 
campaigns provide ample fodder for critics to raise concerns about negative social 
consequences, such as the over-treatment of such conditions (e.g., Applbaum, 2009a; Hart et 
al., 2006). Feminist scholars have been especially critical of pharmaceutical companies’ 
mobilization of gender norms and stereotypes in order to market diverse products including 
drugs for sexual dysfunction, cervical cancer, low testosterone (Low “T”), Alzheimer’s 
disease, fibromyalgia, and migraines (Asberg & Lum, 2009; Barker, 2011; Casper & 
Carpenter, 2008; Fishman, 2004; Kempner, 2006; Watkins, 2013). Additionally, the 
withdrawal of “dangerous” drugs from the market raises scholarly questions about the harms 
that accompany pharmaceuticalization (Abraham & Davis, 2005; Prosser, 2008). Adverse 
drug reactions are now the fourth leading cause of death in the U.S. (Light, 2010). Most 
notable was Merck’s 2004 voluntary withdrawal of Vioxx® from the market when patients 
taking this arthritis drug experienced severe cardiac side effects, including death. This was a 
particularly important example of pharmaceuticalization because extensive advertising led to 
its over-prescription, endangering patients whose arthritis would have benefitted as much or 
more from over-the-counter naproxen with fewer risks (Biddle, 2007).
In reaction to this focus on the negative aspects of pharmaceuticalization, Williams, Martin, 
and Gabe (2011) encourage scholars to see the concept as value-neutral in order to also 
capture positive outcomes. Methodologically, they propose that researchers should view 
pharmaceuticalization as an uneven process that requires empirical investigation to 
determine the extent of the phenomenon in specific cases. While this approach opens up the 
possibility for researchers to analyze societal advantages associated with 
pharmaceuticalization, the recommendation of a case study approach is unlikely to yield this 
desired outcome. As the examples from the literature described above suggest, scholars have 
already primarily engaged pharmaceuticalization through case studies, generally selecting 
specific drugs or industry-constructions of illnesses because they provide rich examples of 
the pharmaceutical industry’s negative influence on society. Similarly, a case study 
approach has the potential to distort the overall picture of the prevalence of certain types of 
products, such as those often referred to as “lifestyle drugs” because of their spurious 
therapeutic value or their continued use by healthy individuals as part of preventive 
maintenance of the body (Dumit, 2012; Williams, Gabe, and Davis, 2008). In examining the 
literature on pharmaceuticalization, it is unclear how dominant these trends are when put in 
the broader context of the pharmaceutical industry’s portfolio of products currently on the 
market or in development.
In contrast, much of the drug development literature examines large-scale trends in the 
industry, but researchers rarely make explicit empirical or conceptual connections to 
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pharmaceuticalization. For example, some scholars have documented the extent to which 
industry-funded research generates results from clinical trials that make the drugs look safer 
and more effective than do independent studies (Healy, 2004; Lexchin et al., 2003). Another 
area of scholarship regarding drug development has focused on the outsourcing of clinical 
trials to contract research organizations, private research companies, and for-profit ethics 
review companies, documenting dramatic changes in how clinical research is conducted 
both in the U.S. and around the world (Fisher, 2009; Lemmens & Freedman, 2000; Petryna, 
2009). These studies have shown the complex, global networks of auxiliary companies that 
work with the pharmaceutical industry to help bring new drugs to market, but they usually 
focus on how clinical trials are organized rather than on the products being developed. A 
final stream of research focuses on specific clinical trials and examines the perspectives of 
enrolled research participants (e.g., Bishop et al., 2012; Lowton, 2005; Morris & Balmer, 
2006). Having some conceptual overlap with literature on pharmaceuticalization, this 
scholarship engages how research participants make sense of elements of study design (like 
randomization and placebo use) in ways that often underscore their desire for medical 
treatment, especially when their access to health care is limited (Stacey et al., 2009; 
Timmermans & McKay, 2009).
One area of scholarship that brings together pharmaceuticalization and R&D focuses on 
innovation. Industry and popular media sources have raised the alarm that the 
pharmaceutical industry is facing an “innovation crisis” in which increasingly fewer 
promising products are being developed or approved by the FDA (Pammolli et al., 2011). 
Social scientists, however, interpret the “crisis” differently. For example, Light and Lexchin 
(2012) show that the decline in new molecules approved since 1996 was only a return from 
a spike to the long-term mean. They argue that the real innovation crisis is the low number 
of clinically superior drugs approved each year since the 1970s. Similarly, Applbaum 
(2009b) has argued that the involvement of marketing teams during drug development 
instead of after market approval has diminished the scientific and clinical value of R&D, 
resulting in a much less innovative industry. Innovation itself is a loaded term when 
analyzing the pharmaceutical industry. Some scholars seem to use it synonymously with 
R&D (e.g., Williams et al., 2011). Others rely on the FDA categorization of pharmaceuticals 
as “new molecular entities” as evidence of innovation (e.g., Abraham, 2010; Carpenter, 
2004), but even this definition gets challenged when scholars criticize the FDA for being 
liberal in its determination of what drugs are novel and what drugs offer significant 
therapeutic advances (Angell, 2004; Davis & Abraham, 2011b).
In spite of the increasing attention to pharmaceuticals by social scientists, there nonetheless 
remains a void in connecting analyses of pharmaceuticalization with larger trends in R&D. 
Case studies about specific drugs have created engaging examples of how new 
pharmaceuticals shape conceptions of health and illness, but it is unclear the extent to which 
these types of drugs are the exception or the norm. Reading this absence in the current 
literature led us to ask what products are in the pharmaceutical industry pipeline, how can 
companies’ drug development investments be characterized, and how could this information 
be mobilized to provide new, accurate insights into patterns of pharmaceuticalization. We 
Fisher et al. Page 5













contextualize our findings by further comparing the diseases targeted by drugs in the 
pharmaceutical pipeline with high mortality diseases in low- versus high-income countries.
Methods
In order to capture a more complete picture of the pharmaceutical industry’s pipeline, we 
created a database of all industry products reported to be in Phase I, II, and III clinical trials 
over a five-year period (2006–2011). Phase IV or postmarketing trials were excluded from 
the database. The database is comprised of information on drug research and development 
from CenterWatch Weekly (CWW), a leading clearinghouse for industry information. 
CWW is a weekly, subscription-only newsletter about important trends and updates on 
industry clinical trials written for professionals working in the pharmaceutical and clinical 
trials industries. We extracted data about investigational drugs and clinical trials from the 
“Drug & Device Pipeline News” (DDPN) from each issue of CWW from July 3, 2006 
(Volume 10, Issue 27) to June 27, 2011 (Volume 15, Issue 26). While not exhaustive, the 
250 weekly reports in this selected five-year timeframe provide a detailed snapshot of the 
industry.
In order to target only industry-sponsored clinical trials, we opted to build our database from 
CWW instead of using ClinicalTrials.gov, the U.S. federal registry of publicly and privately 
sponsored clinical trials. Additionally, the accuracy of ClinicalTrials.gov has been 
questioned because of a lack of reporting standards and underreporting of trials (Heger, 
2012). There are several reasons why companies may be disincentivized to report trials to 
governing agencies, including a desire to avoid reporting of inconclusive results and concern 
for increased federal scrutiny. With self-promotion and marketing the aim of CWW rather 
than regulatory compliance or the reporting of study results, our database presents a more 
streamlined version of the pipeline and may be more inclusive than those reported to 
ClinicalTrials.gov.
Using REDCap electronic data capture tools (Harris et al., 2009) hosted at [removed for 
peer-review], we extracted data, including the pharmaceutical company name, drug name, 
the therapeutic area designated for each drug, and the phase of the trial (I, II, III). We 
included all DDPN entries that reported on drugs that were in Phase I-III clinical trials, and 
we excluded entries that were regulatory updates (e.g., the filing of FDA applications or 
country-specific market approvals).
To assess the general breakdown of trials across disease categories, we assigned each trial an 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) code 
based on the therapeutic area reported in the publication. ICD-9 codes were assigned with 
the assistance of an online resource for classification (http://www.icd9data.com). Entries not 
easily identifiable were researched in more detail using the web and consulting with 
physician colleagues, as needed. Ambiguous diseases and conditions were discussed with a 
second reviewer to reach consensus on the therapeutic area.
In order to compare the number of trials that target diseases in developed and developing 
countries, we used the World Health Organization’s (WHO) lists of the ten leading causes of 
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death in low-income countries (LIC) and high-income countries (HIC) (WHO, 2011; for 
tables of these diseases, see http://www.who.int/mediacentre/factsheets/fs310/en/
index1.html). We opted to focus on illnesses with high rates of mortality because 
measurements of disease prevalence (i.e., morbidity) are notoriously difficult to standardize, 
particularly across countries with widely varying economic resources (Riley 1993; WHO 
2010). Some diseases are leading causes of death worldwide and appear on both lists, so we 
refined our categorization of these diseases into three subgroups: (1) distinct LIC diseases, 
(2) distinct HIC diseases, and (3) high-impact diseases. LIC diseases, thus, includes diseases 
found only on the list of top ten causes of death in low-income countries and excludes those 
found on both the HIC and LIC lists. These distinct LIC diseases include: HIV/AIDS, 
diarrhoael diseases, malaria, and tuberculosis. All clinical trials in our database for drugs 
that targeted these four diseases were coded as 1, otherwise 0, as distinct LIC diseases. 
Similarly, the HIC category includes only those diseases among the top ten causes of death 
in high-income countries that do not also appear on the LIC list. Distinct HIC diseases 
include: chronic obstructive pulmonary disease (COPD), Alzheimer’s disease and other 
dementias, colorectal cancers, trachea bronchus/lung cancers, breast cancer, hypertensive 
heart disease, and diabetes mellitus. All clinical trials in our database for drugs that targeted 
these seven types of diseases were coded as 1, otherwise 0, as distinct HIC diseases. If the 
DDPN did not specify a cancer type, we excluded these clinical trials or drugs from the HIC 
category, thereby creating a more conservative measure of trials and drugs targeting distinct 
HIC diseases. Our use of the term “distinct” here for both LIC and HIC diseases references 
the appearance of these diseases on the WHO lists of the leading causes of death in these 
countries, not the incidence or prevalence of these diseases around the world. Cases of these 
diseases can appear in both types of countries, but they are responsible for a notable share of 
total deaths in one type or the other.
Three causes of death appear on both HIC and LIC top ten lists and these were combined 
with the distinct HIC and LIC diseases to form a high-impact diseases category. 
Overlapping diseases include: lower respiratory infections, ischaemic heart disease, and 
stroke. Based on the WHO’s estimates, the 14 diseases in the combined high-impact 
category accounted for roughly 843 deaths per 100,000 in both high-income and low-income 
countries in 2011. We use the term “high-impact” to note the fact that these diseases account 
for a large number of deaths in both low-income and high-income countries, not that specific 
drugs that target these diseases necessarily have a high-impact on treatment. All clinical 
trials in our database for drugs that targeted a high-impact disease were coded as 1, 
otherwise 0, as high-impact diseases.
To illustrate our constructed categories, references to dementia, colon or rectal cancer, or 
hypertension in the DDPN therapeutic description meant that a clinical trial was classified as 
HIC and High-Impact. Trials that targeted HIV/AIDS, malaria, or tuberculosis were 
classified as LIC and High-Impact, while trials targeting lower respiratory infections or 
strokes were classified as only High-Impact. Therapeutic areas that were coded as 0 across 
all three categories, that is, diseases not considered distinct LIC, HIC, or High-Impact, 
ranged widely from gastroesophageal reflux, inflammatory bowel disease, and Parkinson’s 
disease to pain, asthma, and allergies. Raw numbers were calculated along with percentages 
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of the total database and the ratio of clinical trials and drugs targeting distinct LIC 
therapeutic areas versus those targeting distinct HIC therapeutic areas.
The CWW also reports the companies undertaking the development of specific drugs. To 
assess the types of drugs, diseases targeted, and stage in the pharmaceutical pipeline that the 
top 20 highest-grossing companies invest in, we developed a Top 20 Company category. 
These companies profited from roughly 70% of the market share in worldwide prescription 
drug sales in 2009 (Parexel, 2011). Companies included in this category were the following: 
Pfizer, Merck, Novartis, Roche, Sanofi-Aventis, GlaxoSmithKline, Abbott Laboratories, 
Johnson & Johnson, AstraZeneca, Teva Pharmaceutical, Amgen, Bayer, Eli Lilly, Bristol 
Myers Squibb, Novo Nordisk, Boehringer Ingelheim, Gilead Sciences, Baxter International, 
Takeda, and Daiichi Sankyo. As Wyeth and Schering-Plough were acquired during the five-
year period by Pfizer and Merck, respectively, these were also included in our Top 20 
Company category.
Results
Our five-year snapshot of the pharmaceutical pipeline captured information on 2,477 
investigational drugs in 4,182 clinical trials. The number of clinical trials is greater than the 
number of drugs because our database captured multiple clinical trials and different phases 
of testing for some drugs in the five-year time period. An initial exploration of how the 
drugs were distributed across therapeutic areas resulted in marked differences across ICD-9 
codes (Table 1). We found that the number of drugs targeting neoplasms (i.e., cancers) as a 
disease category far outstripped all other therapeutic areas and represented 26.2% of the 
total pipeline (code #2, n=649). The next most common therapeutic areas were neurological 
diseases (code #6, n=334, 13.5%), infectious and parasitic diseases (code #1, n=260, 
10.5%), and endocrine, metabolic, nutrition and immunity (code #3, n=234, 9.5%). After 
cancers, the individual diseases that were the most common targets of investigational drugs 
were diabetes, pain, HIV/AIDS, and hepatitis C (3.5%, 2.5%, 2.4%, and 2.4% of the 
pipeline, respectively) (see Table 2). In terms of the number of clinical trials reported in 
each phase, 1,497 were in Phase I, 1,935 in Phase II, and 750 in Phase III. Notably more 
clinical trials were in Phase II than Phases I or III.
Looking at the breakdown of the pipeline along targeted diseases of low-income countries 
(LIC) and high-income countries (HIC), Table 3 shows that 83 drugs in 121 clinical trials 
targeted distinct LIC diseases, with 52 in Phase I, 48 in Phase II, and 21 in Phase III (see 
Table 3). In comparison, 287 drugs in 569 clinical trials targeted distinct HIC diseases. 
Across phases, 155 HIC trials were in Phase I, 305 in Phase II, and 109 in Phase III. These 
findings indicate that the number of drugs in the pipeline for distinct HIC diseases outpaced 
those for distinct LIC diseases by 3.46 to 1. Comparing clinical trials for distinct LIC and 
HIC diseases, the number of trials for HIC diseases were 4.70 times that of LIC diseases 
(see Table 3). Because our categorization of distinct LIC and HIC diseases had an uneven 
number of diseases represented (i.e., 4 and 7 respectively), we also calculated a more 
conservative figure for the number of clinical trials related to the top four distinct HIC 
diseases (not shown in the table). For the top four distinct HIC diseases, 262 clinical trials 
were reported for 125 drugs. Using this more conservative estimate, there were 1.50 times 
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more drugs for the top four HIC diseases in the pipeline than for the four distinct LIC 
diseases, and clinical trials for those HIC diseases still outpaced those for LIC diseases by 
2.17 to 1.
Comparing drugs that target distinct LIC and HIC diseases with the total database, HIC 
drugs comprised 11.59% of the 2,477 total drugs in the database while LIC drugs comprised 
3.35%. In terms of clinical trials, distinct HIC and LIC diseases were respectively the target 
of 13.61% and 2.89% of the 4,182 total clinical trials in the database. To account for the 
importance of diseases contributing to the leading causes of death in both LIC and HIC 
contexts, we calculated high-impact diseases by combining the distinct LIC and HIC 
diseases with the three additional diseases that are found in WHO’s lists of the top ten 
causes of death in both high-income and low-income countries (i.e., stroke, ischemic heart 
disease, and lower respiratory infections). There were 492 drugs in 898 clinical trials 
targeting these high-impact diseases, or 19.86% of all investigational drugs and 21.47% of 
clinical trials in the total database (see Table 3). Nearly 80% of all drugs thus targeted 
diseases of lower-impact in terms of mortality.
Looking more closely at one prevalent disease in the developing world, HIV/AIDS 
accounted for 1.6 million deaths worldwide in 2011 (WHO, 2011). Only 59 drugs in 88 
clinical trials targeted the treatment of HIV/AIDS (2.38% of drugs in the database). Among 
HIV/AIDS trials, 34 were in Phase I, 39 in Phase II, and 15 in Phase III. These accounted 
for approximately 23% of drugs and 34% of clinical trials within the infectious and parasitic 
disease category of the ICD-9 (code #1).
The pipeline includes a large proportion of cancer drugs; 651 drugs (26.2%) and nearly a 
third of all reported clinical trials targeted cancer (n = 1,355). By examining the breakdown 
of types of cancers as well as clinical trial phase (shown in Table 4), interesting patterns in 
how pharmaceutical companies prioritize drug development emerge. Specifically, the largest 
percentage of oncology clinical trials (25%) included either unspecified or multiple types of 
cancer listed in the DDPN as the target of intervention. A major trend was that companies 
reported clinical trials for “solid tumors,” “malignancies,” or simply “cancer.” Examples of 
multiple types of cancer include clinical trials reportedly underway for “lung and 
gastrointestinal cancers” and “breast and ovarian cancer.” What is most striking about this 
trend, however, is that the vast majority of clinical trials (80.6%) for unspecified or multiple 
cancers were in Phase I and tapered off dramatically at Phase II (16.7%) and Phase III 
(2.6%).
When examining specific cancers, hematological cancers, including leukemias and 
lymphomas, predominated in clinical trials (21%). The next most common cancer clinical 
trials were lung cancers; prostate cancer; biliary cancers such as liver, gall bladder, and 
pancreatic cancers and breast cancers (see Table 4). Other cancers that had similar 
percentages of clinical trials were gastrointestinal cancers, skin cancers, cancers of the 
female reproductive organs, brain cancers, and urinary cancers. The least represented 
cancers in clinical trials were head and neck cancers, neuroendocrine cancers, metastases, 
and bone cancers.
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Only 4% of the pipeline database included drugs being developed for mental illness. We 
explored the distribution of these 102 drugs in 162 clinical trials because this ICD-9 
category is popular in the literature on pharmaceuticalization. By further classifying mental 
illnesses, the following categories emerged as aggregate therapeutic areas: addiction, 
ADHD, anxiety/depression, autism, insomnia, psychosis, and sexual dysfunction. Clinical 
trials for anxiety/depression (31.5%), addiction (23.5%), and psychosis (23.5%) represented 
nearly 80% of all studies of drugs to treat mental illness. Of the 21 drugs under development 
for addiction, 12 were targeting illicit and prescription drug dependence (57.1%), 3 alcohol 
dependence (14.3%), and 4 nicotine dependence (19%). Additionally, one drug each was 
being tested for gambling addiction and binge eating. Of the remaining mental illnesses, 
insomnia, sexual dysfunction, and ADHD drugs made up respectively 6.8%, 6.2%, and 5.6% 
of the mental illness clinical trials. In the category of sexual dysfunction, two drugs were for 
male premature ejaculation and three were for female dysfunction. Only two drugs were 
under development for autism in five clinical trials (3.1%).
The database included 1,148 companies that were developing investigational drugs. Clinical 
trials reported by the top 20 companies totaled 414 (10% of the total sample), with 294 
drugs in development (12% of the total sample). In terms of phases in the pipeline, top 20 
companies reported 81 trials in Phase I, 146 in Phase II, and 187 in Phase III. This 
represents 5.4% of all Phase I, 7.5% of all Phase II, and 25% of all Phase III trials in the 
database, suggesting that top 20 companies are more likely to invest in the development of 
drugs at Phase III than at Phases I or II. In terms of distinct LIC and HIC diseases, 14 
clinical trials in development by the top 20 companies were for drugs that targeted LIC 
diseases, and 53 were for drugs that targeted HIC diseases.
Looking at the development pipeline, we can see if and how conditions become established, 
ceasing to receive the same investment in research and development over time. Within the 
category of mental illness, clinical trials for drugs related to addiction increased by 200% 
between 2007 and 2010 (see Table 5). In contrast, clinical trials for psychosis and anxiety/
depression decreased by 40% and 38%, respectively. It is possible that investment in drugs 
for illnesses with well-established pharmacological intervention such as psychosis (i.e., 
schizophrenia) and anxiety/depression are on the decline as the industry shifts its investment 
into addiction-drug development. Turning to drug development that targets distinct LIC 
diseases, trials for drugs that treat tuberculosis and malaria remain stagnant, with 0% change 
between 2007 and 2010, while clinical trials for HIV/AIDS-related drugs decreased from 22 
trials reported in 2007 to 14 in 2010, a decline of 36%.
Discussion
Examining drugs at various stages of development in the pharmaceutical pipeline from 2006 
through 2011 provides important insights into the industry’s R&D priorities. Although 
scholars of pharmaceuticalization have given limited attention to cancer drugs (e.g., Davis & 
Abraham, 2011a; Ecks, 2008), these are the biggest class of drugs under development. Much 
of the pharmaceuticalization literature has instead examined drugs that would be categorized 
within the ICD-9 code targeting mental disorders, such as anxiety, depression, insomnia, 
PMDD, and sexual dysfunction. We were surprised to find, however, that drugs targeting 
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these disorders accounted for only 4% of all drugs reportedly under development. Our 
findings also suggest that more sociological analysis is needed of the effects of research and 
development, marketing, and use of pharmaceuticals designed to treat neurological diseases; 
infectious and parasitic diseases; and endocrine, metabolic, nutrition, and immunity 
disorders. In particular, given the prevalence of drugs in the database, more inquiry should 
be directed at the development of pharmaceuticals for the treatment of diabetes, pain, HIV/
AIDS, and hepatitis C (Table 2). Without further investigation into these drugs, our 
understanding of pharmaceuticalization as a process remains myopic and fixated on the 
small portion of drugs that appear frivolous.
Much of the pharmaceuticalization literature has assumed or argued that the pharmaceutical 
industry’s focus for the development and promotion of new drugs is highly Western-centric 
(e.g, Busfield, 2003). As part of our analysis of the pipeline, we analyzed this trend by 
comparing the leading causes of death in low-income countries to those in high-income 
countries. Delving into these high-impact diseases that accounted for almost a quarter of all 
reported clinical trials in the database, we found that the number of drugs in the pipeline was 
roughly 3.5 times higher for distinct HIC diseases than distinct LIC diseases. Even when 
examining a smaller subset of distinct HIC diseases to all distinct LIC diseases, we found 
that there were 2.17 times more clinical trials for HIC diseases. This is only one possible 
metric for assessing the extent to which the pharmaceutical industry prioritizes Western 
diseases. Nonetheless, it is clear that the pharmaceutical industry’s pipeline privileges 
Western diseases over those of developing nations.
Turning to specific therapeutic areas, we focused on HIV/AIDS, cancer, and mental illness. 
We elected to focus on HIV/AIDS and cancer because these were common areas of drug 
development as well as of particular interest to social scientists, especially in terms of social 
movements (e.g, Epstein, 1996; King, 2006). With respect to HIV/AIDS, it was one of the 
more common target diseases for drugs in the pipeline as a whole. After all categorizations 
of cancers, it was the third most prevalent type of drug. However, putting this in perspective 
of the entire pipeline, the 59 HIV/AIDS drugs in development represented only 2.4% of all 
drugs. Moreover, we were surprised to find evidence of possible disinvestment in HIV/
AIDS drugs, with the number of reported clinical trials declining by 36% from 2007 to 
2010. More attention to the implications of this trend for pharmaceuticalization is needed, 
especially when considering the market potential of these drugs given the dramatic drop in 
AIDS mortality rates in Western countries and HIV-positive patients’ dependence on 
antiretrovirals to remain healthy (Maskovsky, 2005).
Making up more than a quarter of all drugs and a third of all clinical trials, pharmaceuticals 
targeting cancers were the most common products in the pipeline. Our most striking finding 
was the number of drugs and clinical trials that either listed multiple types of cancer as the 
target illness or did not specify any particular cancer at all. Our analyses of cancer types by 
clinical trial phase provided some explanation to this pattern of investment in generalized 
cancer therapies. More than 80% of these non-specific cases occurred in Phase I, indicating 
that pharmaceutical companies may primarily focus on testing the safety and tolerability of 
these drugs before defining the targeted types of cancer. Nonetheless, this finding provokes 
a question about how pharmaceutical companies decide which types of cancer become the 
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object of Phase II (and subsequently Phase III) trials. Using the lens of 
pharmaceuticalization, an answer could come from future investigations into the competing 
roles of science, markets, and advocacy groups.
In analyzing the pipeline for mental illness drugs, our goal was to situate much of the 
literature on pharmaceuticalization in the broader context of industry R&D. Psychotropic 
pharmaceuticals make up only a small percentage of investigational drugs (4%). We found 
that the majority of mental illness clinical trials targeted anxiety and depression, but that 
investment in these studies appears to be on the decline given a nearly 40% drop in a four-
year period (2007 – 2010). Likewise, the number of drugs was quite limited for contested 
disorders like sexual dysfunction, ADHD, and insomnia in spite of significant social 
scientific interest in the emergence of these as medical conditions. On the rise, however, 
were clinical trials for drugs related to addiction, which experienced a 200% increase in the 
same time period. Pharmaceuticalization scholarship should account for this rapidly 
developing area of industry R&D, especially given that this trend appears to be a renewed 
interest in old drugs (Campbell & Lovell, 2012).
Finally, we analyzed the pipeline according to the size of the pharmaceutical company to 
determine the share of investigational drugs being developed by the top 20 highest-grossing 
companies in the world. Although the percentages of drugs in the pipeline for these 20 
companies closely reflected the distribution of drugs by therapeutic area of the entire 
dataset, the overall number of drugs was quite small (approximately 12% of the pipeline). 
We also found that these large firms were more likely to be involved with products targeting 
HIC diseases as well as those in Phase III clinical trials. These patterns support industry 
critics’ perspective that the largest pharmaceutical companies are primarily engaged in less 
financially risky R&D and focused on Western markets (Angell, 2004). Additional research, 
however, is needed on collaborations between larger and smaller firms in order to see how 
and when these product handoffs occur. A key area for studies of pharmaceuticalization 
should be additional investigations into drugs being developed by small companies that 
show initial promise in Phase II but fail to move to Phase III because larger companies are 
not interested in investing in these pharmaceuticals.
Limitations
The results reported here rely on industry-reported data that may or may not fully capture 
the true scope of companies’ investment in drug development across Phases I - III. Previous 
research in pharmaceuticalization has focused on drugs already on the market rather than 
industry’s R&D investment prior to approval. Although the five-year period covered in the 
data includes 2,477 investigational drugs in 4,182 clinical trials, it provides only an initial 
snapshot of drug development and cannot fully address long-term trends in the industry. 
While we believe that this database has distinct advantages over alternatives like 
ClinicalTrials.gov, it is clear that its self-reported nature limits our ability to draw firm 
conclusions. Future work on the pharmaceutical pipeline should address these limitations by 
seeking out more exhaustive data sources on drug development prior to market approval that 
cover longer periods of time. A second limitation of the current study is our reliance on 
measures of mortality rather than morbidity. While our decision to use the WHO’s top ten 
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causes of death is based on the difficulties in measuring disease prevalence in low-income 
countries, future analysis should examine the extent to which drug development may target 
diseases based on prevalence rather than those that have a high-impact on population 
mortality.
Conclusion
We constructed a database of drug development reported over a five-year period as a 
window into the pharmaceutical industry’s R&D priorities. The industry’s investment in 
“innovation” has been both in research and marketing to meet its need for ever-expanding 
markets and increasingly profitable new drugs (Angell, 2004; Greene, 2007). With the 
pharmaceuticalization literature emphasizing disease-mongering and the “transformation of 
human conditions” across a spectrum of established and newly redefined conditions 
(Williams et al., 2011: 711), we wanted our database to help establish a context for these 
case studies. Abraham (2010) previously noted that “sociological debate about 
pharmaceuticalization and medicalization revolves almost exclusively around psycho-social 
or ‘lifestyle’ areas of medicine and associated pharmaceuticals to treat sexual activity, sleep 
disorders, social anxiety, hyperactivity, attention difficulties and depression” (605). Like 
Abraham, we share the concern that the centrality of these areas within the social sciences 
reflects the Western-centrism of both the industry and scholarship and simultaneously 
narrows our understanding of broader trends and processes.
Our findings confirm some of the major critiques made of the pharmaceutical industry, but 
they also indicate that, taken as a whole, pharmaceuticalization case studies published to 
date might exaggerate the industry’s investment in drugs for spurious diseases. For example, 
the Western influences that Busfield (2003) observes in the pharmaceutical industry overall 
and that seem to be borne out in our data suggest that the ratio of gains and losses varies 
based on global positioning. Etkin (1992) argues that “too many varieties of pharmaceuticals 
have been exported to the Third World. The specific categories of drugs selected for export 
have reflected less the local epidemiologic patterns than they have diseases prevalent in their 
countries of origin” (99). Moreover, groups like Doctors without Borders claim that the 
fundamental problem for the developing world is not the development of new drugs but 
reliable access to essential drugs (Pecoul et al., 1999). Perhaps as Williams, Martin, and 
Gabe (2011) claim, pharmaceuticalization as a conceptual process is value-neutral, but the 
implementation of that process through resource allocation in the drug development pipeline 
privileges drug treatments that target profitable Western illnesses over those in non-Western 
parts of the world.
Our analysis of the pipeline also underscores the important sociological work still to be done 
on the plethora of “legitimate,” high-impact diseases that pharmaceutical companies are 
targeting with investigational drugs. This is especially important when much evidence 
suggests that the newest pharmaceuticals do not offer much therapeutic value in the 
treatment of these conditions (Light, Lexchin, and Darrow, 2013). The field needs in-depth 
case studies of pharmaceuticals being developed to treat cancer, HIV/AIDS, hepatitis C, 
diabetes, and pain to explore how the development of these products can add new insights 
into processes of pharmaceuticalization underway in Western societies. Recognizing the 
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prevalence of particular pharmaceuticals in the pipeline can direct scholarship towards the 
politics of research in important therapeutic areas where less is known about how drugs are 
marketed to and used by consumers.
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• 3.46 times more drugs being developed target diseases of high-income 
countries.
• The majority of pharmaceuticals being developed are cancer treatments.
• Only 4% of the pharmaceuticals being developed are for mental illness.
• The 20 biggest pharmaceutical companies are developing only 12% of all drugs.
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Visualization of the Pharmaceutical Pipeline
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Table 1
ICD-9-CM Disease Categories and Totals for 2,477 Drugs in the Database
ICD-9 Therapeutic Area Total n %
2 Neoplasm 649 26.20
6 Diseases of the Nervous System and Sense Organs 334 13.48
1 Infectious and Parasitic Diseases 260 10.50
3 Endocrine, Nutritional and Metabolic Diseases, and Immunity Disorders 234 9.45
8 Diseases of the Respiratory System 168 6.78
7 Diseases of the Circulatory System 147 5.93
13 Diseases of the Musculoskeletal System and Connective Tissue 119 4.80
9 Diseases of the Digestive System 100 4.04
5 Mental Disorders 102 4.12
12 Diseases of the Skin and Subcutaneous Tissue 98 3.96
10 Diseases of the Genitourinary System 71 2.87
17 Injury and Poisoning 63 2.54
4 Diseases of the Blood and Blood Forming Organs 57 2.30
16 Symptoms, Signs, and Ill-Defined Conditions 50 2.02
Suppl V Supplementary Classification of Factors Influencing Health Status and Contact with Health Services 11 0.44
Suppl E Supplementary Classification of External Causes of Injury and Poisoning 6 0.24
14 Congenital Anomalies 6 0.24
11 Complications of Pregnancy, Childbirth, and the Puerperium 1 0.04
15 Certain Conditions Originating in the Perinatal Period 1 0.04
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Table 2
Most Common Diseases Represented in the Database
ICD-9 Therapeutic Area Drugs (n) % of “Pipeline”
2 Cancer* 649 26.2
3 Diabetes 87 3.5
6 Pain 62 2.5
1 HIV/AIDS 59 2.4
1 Hepatitis C 59 2.4
8 Influenza 55 2.2
13 Arthritis 48 1.9
6 Alzheimer’s 31 1.3
12 Psoriasis 29 1.2
8 Asthma 28 1.1
6 MS 27 1.1
3 Diabetes-related 27 1.1
6 Parkinson’s 26 1.0
8 Allergies 21 0.8
7 Hypertension 19 0.8
*
See Table 4 for distribution of clinical trials by cancer type.
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Table 3
Clinical Trials and Drugs that Target LIC, HIC, and High-Impact Disease Categories
Category # of Trials # of Drugs % of Total Trials
Distinct LIC* 121 83 2.89
 Phase I 52
 Phase II 48
 Phase III 21
Distinct HIC** 569 287 13.61
 Phase I 155
 Phase II 305
 Phase III 109
High-Impact*** 898 492 21.47
 Phase I 298
 Phase II 446
 Phase III 154
Ratio of HIC to LIC 4.70:1 3.46:1
*
Distinct Low- Income Country Diseases = HIV/AIDS, diarrhoael diseases, malaria, and tuberculosis
**
Distinct High-Income Country Diseases = chronic obstructive pulmonary disease (COPD), Alzheimer’s disease and other dementias, colorectal 
cancers, trachea bronchus/lung cancers, breast cancer, hypertensive heart disease, and diabetes mellitus
***
High-Impact = Combined total of distinct LIC, distinct HIC, plus diseases that overlap both lists of the top ten causes of death (i.e., stroke, 
ischemic heart disease, and lower respiratory infections, WHO 2011, see http://www.who.int/mediacentre/factsheets/fs310/en/index1.html)
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Table 4
Total Clinical Trials in Neoplasm/Oncology Subcategories
Category % of Neoplasms
Cancer - Unspecified 25.0
Hematological (e.g., leukemias and lymphomas) 21.0
Lung 7.8
Prostate 6.9
Biliary (e.g., pancreas, gall bladder, and liver cancers) 6.7
Breast 6.3
Gastrointestinal (e.g., colon, rectal, stomach, and esophageal cancers) 5.0
Skin 4.6
Female Reproduction (e.g., cervical, uterine, endometrial, and ovarian cancers) 4.3
Brain 4.1
Urinary (e.g., kidney and bladder cancers) 3.2
Head and Neck 2.1
Neuroendocrine (e.g., adrenal and thyroid cancers) 1.7
Metastases 0.8
Bone 0.1
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